2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
- Author:
Mee Kyoung KIM
1
;
Seung Hyun KO
;
Bo Yeon KIM
;
Eun Seok KANG
;
Junghyun NOH
;
Soo Kyung KIM
;
Seok O PARK
;
Kyu Yeon HUR
;
Suk CHON
;
Min Kyong MOON
;
Nan Hee KIM
;
Sang Yong KIM
;
Sang Youl RHEE
;
Kang Woo LEE
;
Jae Hyeon KIM
;
Eun Jung RHEE
;
SungWan CHUN
;
Sung Hoon YU
;
Dae Jung KIM
;
Hyuk Sang KWON
;
Kyong Soo PARK
;
Author Information
- Publication Type:Practice Guideline
- Keywords: Diabetes mellitus, type 2; Diagnosis; Practice guideline; Therapeutics
- MeSH: Blood Pressure; Diabetes Mellitus, Type 2; Diagnosis; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Korea; Obesity; Overweight
- From:Diabetes & Metabolism Journal 2019;43(4):398-406
- CountryRepublic of Korea
- Language:English
- Abstract: The Committee of Clinical Practice Guidelines of the Korean Diabetes Association revised and updated the 6th Clinical Practice Guidelines in 2019. Targets of glycemic, blood pressure, and lipid control in type 2 diabetes mellitus (T2DM) were updated. The obese and overweight population is increasing steadily in Korea, and half of the Koreans with diabetes are obese. Evidence-based recommendations for weight-loss therapy for obesity management as treatment for hyperglycemia in T2DM were provided. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with T2DM were incorporated into the recommendations.
